Biotech medicines proteins made by altering the DNA of bacteria and yeast or mammal cells and infused into sick patients are the fastest growing category of health spending. Sales extended $40 billion in 2006 when reports indicated there were more than 400 biotech products being synthesized to treat AIDS, cancer, diabetes, Alzheimer's and a hundred other diseases. The manufacture of biotech's is more complex as well as costly than conventional medicine and the cost to patients can run as high as $25,000-50,000 a year. Some members of Congress have familiarised legislation that would give consumers access to lower-cost copies one would approve the FDA to approve safe, lower-cost versions of biotechnology medicines without the full range of tests normally required for new products.

Please deliver at least a paragraph for each of the below questions:

1) Describe who the stakeholders are who will be affected by such legislation.

2) Create arguments for also against the legislation.